Takeda’s study of subcutaneous vedolizumab meets primary goal

Vedolizumab IV has approvals to treat moderately to severely active Crohn’s disease and ulcerative colitis in certain patients. Credit: RicHard-59.



  • Takeda’s study of subcutaneous vedolizumab meets primary goal